Decera Clinical Education Oncology Podcast

00:24:04

Incorporating AKT1 and PIK3CA Pathway Testing and...

Decera Clinical Education Oncology Podcast ·

2026/06/30

Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer. Presenters: Cristina Saura Manich, MD, PhD Head, Breast Cancer Unit Medical Oncology Service Vall d'Hebron University Hospital Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain Giampaolo Bianchini, MD Associate Professor, Universita

en

00:26:58

Personalizing EGFR Mutation–Positive NSCLC Care:...

Decera Clinical Education Oncology Podcast ·

2026/06/22

Link to claim CME credit: https://bit.ly/4uRr3ir In this episode, Elizabeth Krueger, NP, and Sam Vafadar, DHSc, PA-C, discuss how they optimize first-line EGFR-targeted therapy for patients with EGFR-mutated NSCLC, including: First-line treatment options available for EGFR-mutated NSCLC and the clinical trials that resulted in their approval Adverse event identification and management Generalized strategies to support patient adherence to TKIs Get access to all of our new podcasts by

en

00:27:23

Advancing the Early Detection of Lung Cancer:...

Decera Clinical Education Oncology Podcast ·

2026/06/09

In this episode, Dr Abbie Begnaud discusses the importance of lung cancer screening and evolving strategies to improve early detection among high-risk populations, including:Low-dose CT screening, which reduces lung cancer mortality by detecting cancers at earlier, more treatable stages Updated screening guidelines that have expanded eligibility Key challenges that impact screening participation, including awareness, access, and broader risk assessment Get access to all of our new podcasts by

en

00:26:24

HNSCC: Current and Emerging Therapeutic Strategies

Decera Clinical Education Oncology Podcast ·

2026/05/29

In this episode, Dr Aarti Bhatia and Dr Deborah Wong discuss the rapidly evolving treatment landscape for recurrent, metastatic, and locally advanced head and neck squamous cell carcinoma (HNSCC), including the growing role of immune checkpoint inhibitors, perioperative treatment strategies, EGFR-targeted bispecific antibodies, antibody–drug conjugates, HPV-targeted vaccines, and novel radiosensitizers. The discussion also explores emerging phase III clinical trials, treatment sequencing

en

00:20:50

Navigating Relapsed/Refractory Multiple Myeloma:...

Decera Clinical Education Oncology Podcast ·

2026/05/15

In this episode, hear Doris K. Hansen, MD, discuss the management of relapsed/refractory multiple myeloma with bispecific antibodies including:Practical differences among approved bispecific antibodies Toxicity profiles of approved bispecific antibodies When to refer patients for evaluation for immunotherapies Considerations for sequencing bispecific antibodies in the relapsed/refractory setting New findings with combination regimens with bispecific antibodies Program faculty: Doris K

en

00:31:00

Oncologists “On Call”: Our Practical Experiences to...

Decera Clinical Education Oncology Podcast ·

2026/05/07

In this episode, Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, discuss various strategies to optimize the use of bispecific antibodies in their practices for the treatment of R/R MM through patient monitoring, dosing in outpatient settings, and using tocilizumab and IVIG, among other management strategies. Presenters: Muhamed Baljevic, MD, FACP Associate Professor of Medicine Division of Hematology-Oncology Department of Medicine Director, Multiple Myeloma Program Director, Vanderbilt

en

00:22:08

Thrombotic Events and ET/PV: What You Should Know

Decera Clinical Education Oncology Podcast ·

2026/04/30

In this episode, hear Anthony Hunter, MD and Douglas Tremblay, MD discuss the various presentations of thrombotic events in patients with PV or ET including how thrombotic events may lead to diagnosis: PV and ET increase the risk of both arterial and venous thrombotic events Unusual thrombotic events Thrombosis as initial presentation for MPN Case presentations Brief overview of thrombosis management Program faculty: Anthony M. Hunter, MD Associate Professor, Department of Hematology and

en

00:17:21

Global Experts Discuss Current and Emerging...

Decera Clinical Education Oncology Podcast ·

2026/04/30

In this podcast episode, Ciro Rinaldi MD, PhD, and Alessandro M. Vannucchi, MD, discuss contemporary management of essential thrombocythemia (ET) and polycythemia vera (PV), as well as novel investigational approaches, including the following: Overview of current treatment paradigms for PV and ET Importance of shared decision-making and patient communication in determining treatment Current therapeutic areas of need in ET and PV Emerging investigational therapeutics Presenters: Ciro Rinaldi

en

00:14:55

Global Experts Discuss Diagnostic Considerations in...

Decera Clinical Education Oncology Podcast ·

2026/04/29

In this podcast episode, Ciro Rinaldi, MD, PhD, and Alessandro M. Vannucchi, MD, as they discuss contemporary topics in diagnosing essential thrombocythemia (ET) and polycythemia vera (PV), including: Overview of diagnostic criteria for PV and ET Importance of bone marrow biopsy Degree of suspicion of PV/ET in patients presenting with thrombotic events Pearls of wisdom in diagnosis Presenters: Ciro Rinaldi, MD, PhD Chief Medical Officer, United Lincolnshire Teaching Hospital Honorary

en

00:22:41

Experts Discuss Novel Approaches to First-line...

Decera Clinical Education Oncology Podcast ·

2026/04/17

In this podcast episode, Erika Hamilton, MD, FASCO, and Ian Krop, MD, PhD, discuss recent developments in the field of first-line therapy and maintenance treatment for patients with HER2-positive metastatic breast cancer, including the following:Trastuzumab deruxtecan plus pertuzumab as first-line therapy based on data from DESTINY-Breast09 Adding palbociclib to HP and ET as maintenance therapy for HR-positive/HER2-positive MBC, based on data from PATINA Adding tucatinib to HP as maintenance

en

00:41:42

Patient Voices: Caring for the Whole Patient and...

Decera Clinical Education Oncology Podcast ·

2026/04/15

A patient advocate/cancer survivor and a healthcare professional discuss key topics including early breast cancer diagnosis, role of self-agency in pursuing optimal cancer care, encouraging trial participation with patient testimonials, and other considerations for the patient care journey such as appropriate screening, follow-up encounters for questions, guideline-based treatments, and side effect management. Participants Kristen D. Whitaker, MD, MS Breast Medical Oncologist Medstar Georgetown

en

00:31:22

Role of AKT and PI3K Inhibitors in Patients With...

Decera Clinical Education Oncology Podcast ·

2026/04/15

Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices. Presenters: Nadia Harbeck, MD Breast Cancer Director Department of OB&GYN and Comprehensive Cancer Center Munich LMU University Hospital Munich, Germany Francois-Clement Bidard, MD, PhD Breast Medical Oncology Institut Curie & University of Versailles

en

00:44:46

Patient-Centered Management of CDK4/6 Inhibitor...

Decera Clinical Education Oncology Podcast ·

2026/04/14

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss patient-centered management of CDK4/6 inhibitor therapy in HR-positive/HER2-negative breast cancer, with a focus on how oncology pharmacists and the multidisciplinary care team can support patients through treatment, including: Practical strategies for monitoring and managing key adverse events associated with abemaciclib, ribociclib, and palbociclib, such as diarrhea, neutropenia, hepatotoxicity, and QT

en

00:33:13

TROP2-Directed Antibody–Drug Conjugates in...

Decera Clinical Education Oncology Podcast ·

2026/04/13

In this episode, Dr Matthew Gubens and Dr Helena Yu discuss the evolving role of TROP2-directed therapies in non-small-cell lung cancer, with a focus on how antibody–drug conjugates (ADCs) fit into current treatment strategies, including The mechanism of action and clinical trial outcomes of TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan Use of these therapies in EGFR-mutant disease and how they fit into a changing treatment landscape Practical advice on associated

en

00:39:12

Emerging Therapies for Patients With HER2+...

Decera Clinical Education Oncology Podcast ·

2026/04/13

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the individualized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer, including: A brief overview of BTC and GEA Notable findings from a recent survey of healthcare professionals on BTC and GEA Case studies on recommended management of patients with BTC or GEA Emerging datasets of HER2-directed therapies in BTC and GEA affecting clinical

en

00:19:16

Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC

Decera Clinical Education Oncology Podcast ·

2026/03/26

In this podcast episode, Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, discuss ADCs for HER2-negative/ultralow/low metastatic breast cancer, including:Classifying HER2 expression in MBC today (HER2 negative/ultralow/low/positive) and why this is important ADCs for HER2-negative/ultralow/low MBC Patient communication: best practices in discussing treatment goals and potential AEs Presenters: Aditya Bardia, MD, MPH, FASCO Professor of Medicine Geffen School of Medicine University of

en

00:18:57

Bladder Cancer Breakthroughs: New NMIBC Therapies and...

Decera Clinical Education Oncology Podcast ·

2026/03/23

In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including: New treatment options for BCG-unresponsive non–muscle-invasive bladder cancer Intravesical therapies such as nadofaragene and N-803 The role of ctDNA in measurable

en

00:25:11

Myth vs Medicine: Pharmacist’s Perspective on...

Decera Clinical Education Oncology Podcast ·

2026/03/20

In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making.Presenters: Rodney Hunter, PharmD, BCOP Director of Clinical Services Memorial Hermann Texas Medical Center Clinical Pharmacy Specialist University of Texas Health

en

00:33:23

Advanced Practice Professionals on Biomarker Testing...

Decera Clinical Education Oncology Podcast ·

2026/03/19

Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker for all

en

00:22:22

Advanced Practice Professionals on Biomarker Testing...

Decera Clinical Education Oncology Podcast ·

2026/03/13

Listen to this audio podcast covering biomarker testing in patients with prostate cancer. Learn from Sara Traverso, MMS, PA-C, and Brenda Martone, MSN, ANP-BC, AOCNP, about when to conduct germline and somatic genetic testing in patients with prostate cancer, discussing testing with patients and their caregivers, recognizing actionable biomarkers, and improving APP confidence in the application of biomarker testing results to practice.Presenters: Sara Traverso, MMS, PA-C Physician Assistant

en

All Episodes

Similar Podcasts

Les dents et dodo

BFMTV

Daily Facts

Amalia Dupray and Montgomery Jones.

Education Futures

Svenia Busson & Laurent Jolie

Out In The Hall

NHSA

Reading Teachers Lounge

Shannon Betts and Mary Saghafi